
News|Videos|June 17, 2024
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Author(s)Ibiayi Dagogo-Jack, MD
CROWN (NCT03052608) is a phase 3 clinical trial evaluating progression free survival with the use of loratinib in patients with advanced ALK+ NSCLC.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer
2
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
3
ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention
4
Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer
5





















































